世界の皮膚糸状菌性爪真菌症治療薬(DOT)市場

• 英文タイトル:Global Market Study on Dermatophytic Onychomycosis Therapeutics (DOT): Increasing Preference for Topical Treatment Complementing Market Growth

Global Market Study on Dermatophytic Onychomycosis Therapeutics (DOT): Increasing Preference for Topical Treatment Complementing Market Growth「世界の皮膚糸状菌性爪真菌症治療薬(DOT)市場」(市場規模、市場予測)調査レポートです。• レポートコード:PMR21SE018
• 出版社/出版日:Persistence Market Research / 2021年7月14日
• レポート形態:英文、PDF、205ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥553,700 (USD4,900)▷ お問い合わせ
  Site Licence¥858,800 (USD7,600)▷ お問い合わせ
  Enterprisewide¥1,197,800 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Persistence Market Research社の本調査レポートは、皮膚糸状菌性爪真菌症治療薬(DOT)の世界市場について調査し、エグゼクティブサマリー、市場イントロダクション、市場機会分析、市場背景、マクロ経済仮定、世界経済展望、市場分析/予測、予測要因:関連性・影響、予測仮定、競争分析、地域別分析、製品種類別(タブレット、ネイルペイント)分析、治療別(経口、局所)分析、エンドユーザー別(病院、クリニック、独立薬局、通信販売薬局、ドラッグストア)分析、調査手法などを掲載しています。
・エグゼクティブサマリー
・市場イントロダクション
・市場機会分析
・市場背景
・マクロ経済仮定
・世界経済展望
・市場分析/予測
・予測要因:関連性・影響
・予測仮定
・競争分析
・皮膚糸状菌性爪真菌症治療薬(DOT)の世界市場規模:地域別
・皮膚糸状菌性爪真菌症治療薬(DOT)の世界市場規模:製品種類別(タブレット、ネイルペイント)
・皮膚糸状菌性爪真菌症治療薬(DOT)の世界市場規模:治療別(経口、局所)
・皮膚糸状菌性爪真菌症治療薬(DOT)の世界市場規模:エンドユーザー別(病院、クリニック、独立薬局、通信販売薬局、ドラッグストア)
・調査手法

Dermatophytic Onychomycosis Therapeutics (DOT) Market: Report Scope

This Persistence Market Research report examines the global dermatophytic onychomycosis therapeutics (DOT) market for the period 2021–2031. The primary objective of the report is to offer updates and information related to opportunities in the global dermatophytic onychomycosis therapeutics market.

A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, market attractive index. The forecast of the DOT market by country, product type, treatment type and end users is represented in a tabular form for each region. This section will help to understand the present scenario and opportunity of the dermatophytic onychomycosis therapeutics market in major countries by each segment.

In the next section of the report, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view of the key competitor firms in order to access the key differentiators among the competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to a market segment.

The detailed profiles of players operating in the DOT market are also provided in the report, which highlight company description, product/segment overview, SWOT analysis, financial information, key developments related to market and strategic overview.

The next section of the report highlights the market outlook for 2021–2031 and sets the forecast within the context of the dermatophytic onychomycosis therapeutics market by region. The key regions assessed in this report include North America, Latin America, Europe, Asia Pacific, and MEA. A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index.

The above sections – by product type, treatment type and end user – evaluate the historic market analysis and growth prospects of the dermatophytic onychomycosis therapeutics market for the period 2021–2031. We have considered 2020 as the base year and provided data for the forecast period.

The final section of the report represents the global scenario of the dermatophytic onychomycosis therapeutics market along with y-o-y growth and market forecast till 2031. This section also evaluates the global market opportunity over the forecast period as well as the absolute dollar opportunity for each year. This section will help to understand the overall market growth for dermatophytic onychomycosis therapeutics and the opportunity analysis for every year over the forecast period.

To arrive at the market size, bottom-up approach is used to validate the total market size obtained for dermatophytic onychomycosis therapeutics market. The forecast presented in the report provides total revenue of the dermatophytic onychomycosis therapeutics market over 2021–2031.

Persistence Market Research uses a triangulation methodology that is primarily based on experimental techniques such as patient-level data to obtain precise market estimations for dermatophytic onychomycosis therapeutics market and insights on specific country/regions. The country specific data is again analyzed to derive data at a regional level and then at a global level. This methodology ensures high quality and accuracy of information.

Several factors that were considered while developing market estimates for dermatophytic onychomycosis therapeutics market were disease epidemiology, treatment seeking rate, ratio of population prescribed with nail paints and oral drugs, dosage and prescription pattern and compliance rate.

Average Selling Price (US$) are derived by using weighted average pricing methodology.

On the other hand, Persistence Market Research also analyzed the market by considering the revenue from the key players operating in this segment. Key Players are segmented at a Tier-level with respect to their revenues, product portfolio and geographical presence.

This process involves analysis of various companies’ annual reports, Investors presentations, SEC filings, 10k reports, earning call transcripts and press releases. This task is done to fetch substantial information about the key players, their respective revenues and estimate their respective market share.

Revenue growth of key market players is analyzed over the historical period and qualitative assessment of new product launches and innovations has been made in order to validate and align the resultant market numbers.

Market structure is closely studied and analyzed at regional level to map and ascertain incremental $ opportunity for companies for instance, supply from domestic/regional players, small-scale enterprises or unorganized segments is also taken into consideration to arrive at final market numbers.

While forecasting the market size for dermatophytic onychomycosis therapeutics market, we have considered the impact of several factors such as per capital healthcare expenditure, disposable income, new product launches and approvals for dermatophytic onychomycosis therapeutics, penetration of dermatophytic onychomycosis therapeutics market products through various end users, generic penetration across all regions, etc.

However, quantifying the market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

レポート目次

Table of Content

1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy

3. Dermatophytic Onychomycosis Therapeutics Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis

4. Market Background
4.1. List of Growth Hacking Manufacturers
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
4.3. Regulatory Scenario

5. Macroeconomic Assumptions

6. Global Economic Outlook
6.1. Gross Domestic Product by Region & Country, 2016 – 2031
6.2. Global Healthcare Outlook

7. North America Dermatophytic Onychomycosis Therapeutics Market Analysis 2016-2020 and Forecast 2021–2031
7.1. Introduction
7.2. Regional Trend
7.3. Historical Market Size (US$ Mn) and Trend Analysis By Country, 2021-2031
7.3.1. U.S.
7.3.2. Canada
7.4. Market Size (US$ Mn) and Forecast By Country, 2021-2031
7.5. Historical Market Size (US$ Mn) and Trend Analysis By Product Type, 2021-2031
7.5.1. Tablets
7.5.1.1. Rx
7.5.1.2. OTC
7.5.2. Nail Paints
7.5.2.1. Rx
7.5.2.2. OTC
7.6. Market Size (US$ Mn) and Forecast By Product Type, 2021-2031
7.7. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2021-2031
7.7.1. Oral
7.7.2. Topical
7.8. Market Size (US$ Mn) Forecast By Treatment Type, 2021-2031
7.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2021-2031
7.9.1. Hospitals
7.9.2. Clinics
7.9.3. Independent Pharmacies
7.9.4. Mail Order Pharmacies
7.9.5. Drug Stores
7.10.Market Size (US$ Mn) Forecast By End User, 2021-2031
7.11.Market Attractiveness Analysis
7.11.1. By Country
7.11.2. By Product Type
7.11.3. By Treatment Type
7.11.4. By End User
7.12.Drivers and Restraints: Impact Analysis
7.13.Key Market Participants – Intensity Mapping

8. Latin America Dermatophytic Onychomycosis Therapeutics Market Analysis 2016-2020 and Forecast 2021–2031
8.1. Introduction
8.2. Regional Trend
8.3. Historical Market Size (US$ Mn) and Trend Analysis By Country, 2021-2031
8.3.1. Brazil
8.3.2. Mexico
8.3.3. Argentina
8.3.4. Rest of Latin America
8.4. Market Size (US$ Mn) and Forecast By Country, 2021-2031
8.5. Historical Market Size (US$ Mn) and Trend Analysis By Product Type, 2021-2031
8.5.1. Tablets
8.5.1.1. Rx
8.5.1.2. OTC
8.5.2. Nail Paints
8.5.2.1. Rx
8.5.2.2. OTC
8.6. Market Size (US$ Mn) and Forecast By Product Type, 2021-2031
8.7. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2021-2031
8.7.1. Oral
8.7.2. Topical
8.8. Market Size (US$ Mn) Forecast By Treatment Type, 2021-2031
8.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2021-2031
8.9.1. Hospitals
8.9.2. Clinics
8.9.3. Independent Pharmacies
8.9.4. Mail Order Pharmacies
8.9.5. Drug Stores
8.10.Market Size (US$ Mn) Forecast By End User, 2021-2031
8.11.Market Attractiveness Analysis
8.11.1. By Country
8.11.2. By Product Type
8.11.3. By Treatment Type
8.11.4. By End User
8.12.Drivers and Restraints: Impact Analysis
8.13.Key Market Participants – Intensity Mapping

9. Europe Dermatophytic Onychomycosis Therapeutics Market Analysis 2016-2020 and Forecast 2021–2031
9.1. Introduction
9.2. Regional Trend
9.3. Historical Market Size (US$ Mn) and Trend Analysis By Country, 2021-2031
9.3.1. Germany
9.3.2. France
9.3.3. U.K
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Market Size (US$ Mn) and Forecast By Product Type, 2021-2031
9.5. Historical Market Size (US$ Mn) and Trend Analysis By Product Type, 2021-2031
9.5.1. Tablets
9.5.1.1. Rx
9.5.1.2. OTC
9.5.2. Nail Paints
9.5.2.1. Rx
9.5.2.2. OTC
9.6. Market Size (US$ Mn) and Forecast By Product Type, 2021-2031
9.7. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2021-2031
9.7.1. Oral
9.7.2. Topical
9.8. Market Size (US$ Mn) Forecast By Treatment Type, 2021-2031
9.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2021-2031
9.9.1. Hospitals
9.9.2. Clinics
9.9.3. Independent Pharmacies
9.9.4. Mail Order Pharmacies
9.9.5. Drug Stores
9.10.Market Size (US$ Mn) Forecast By End User, 2021-2031
9.11.Market Attractiveness Analysis
9.11.1. By Country
9.11.2. By Product Type
9.11.3. By Treatment Type
9.11.4. By End User
9.12.Drivers and Restraints: Impact Analysis
9.13.Key Market Participants – Intensity Mapping

10. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Analysis 2016-2020 and Forecast 2021–2031
10.1.Introduction
10.2.Regional Trend
10.3.Historical Market Size (US$ Mn) and Trend Analysis By Country, 2021-2031
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. Australia and New Zealand
10.3.5. Rest of Asia Pacific
10.4.Market Size (US$ Mn) and Forecast By Country, 2021-2031
10.5.Historical Market Size (US$ Mn) and Trend Analysis By Product Type, 2021-2031
10.5.1. Tablets
10.5.1.1. Rx
10.5.1.2. OTC
10.5.2. Nail Paints
10.5.2.1. Rx
10.5.2.2. OTC
10.6.Market Size (US$ Mn) and Forecast By Product Type, 2021-2031
10.7.Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2021-2031
10.7.1. Oral
10.7.2. Topical
10.8.Market Size (US$ Mn) Forecast By Treatment Type, 2021-2031
10.9.Historical Market Size (US$ Mn) Trend Analysis By End User, 2021-2031
10.9.1. Hospitals
10.9.2. Clinics
10.9.3. Independent Pharmacies
10.9.4. Mail Order Pharmacies
10.9.5. Drug Stores
10.10.Market Size (US$ Mn) Forecast By End User, 2021-2031
10.11.Market Attractiveness Analysis
10.11.1. By Country
10.11.2. By Product Type
10.11.3. By Treatment Type
10.11.4. By End User
10.12.Drivers and Restraints: Impact Analysis
10.13.Key Market Participants – Intensity Mapping

11. Middle East and Africa (MEA) Dermatophytic Onychomycosis Therapeutics Market Analysis 2016-2020 and Forecast 2021–2031
11.1.Introduction
11.2.Regional Trend
11.3.Historical Market Size (US$ Mn) and Trend Analysis By Country, 2021-2031
11.3.1. South Africa
11.3.2. GCC
11.3.3. Rest of MEA
11.4.Market Size (US$ Mn) and Forecast By Country, 2021-2031
11.5.Historical Market Size (US$ Mn) and Trend Analysis By Product Type, 2021-2031
11.5.1. Tablets
11.5.1.1. Rx
11.5.1.2. OTC
11.5.2. Nail Paints
11.5.2.1. Rx
11.5.2.2. OTC
11.6.Market Size (US$ Mn) and Forecast By Product Type, 2021-2031
11.7.Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2021-2031
11.7.1. Oral
11.7.2. Topical
11.8.Market Size (US$ Mn) Forecast By Treatment Type, 2021-2031
11.9.Historical Market Size (US$ Mn) Trend Analysis By End User, 2021-2031
11.9.1. Hospitals
11.9.2. Clinics
11.9.3. Independent Pharmacies
11.9.4. Mail Order Pharmacies
11.9.5. Drug Stores
11.10.Market Size (US$ Mn) Forecast By End User, 2021-2031
11.11.Market Attractiveness Analysis
11.11.1. By Country
11.11.2. By Product Type
11.11.3. By Treatment Type
11.11.4. By End User
11.12.Drivers and Restraints: Impact Analysis
11.13.Key Market Participants – Intensity Mapping

12. Forecast Factors: Relevance and Impact

13. Forecast Assumptions

14. Competition Analysis
14.1.Competition Dashboard
14.2.Company Profiles
14.2.1. Valeant Pharmaceuticals Inc.
14.2.1.1. Overview
14.2.1.2. Product and End User Portfolio
14.2.1.3. Production Footprint
14.2.1.4. Sales Footprint
14.2.1.5. Channel Footprint
14.2.1.6. Strategy
14.2.1.6.1. Marketing Strategy
14.2.1.6.2. Product Strategy
14.2.1.6.3. Channel Strategy
14.2.2. Galderma S.A.
14.2.2.1. Overview
14.2.2.2. Product and End User Portfolio
14.2.2.3. Production Footprint
14.2.2.4. Sales Footprint
14.2.2.5. Channel Footprint
14.2.2.6. Strategy
14.2.2.6.1. Marketing Strategy
14.2.2.6.2. Product Strategy
14.2.2.6.3. Channel Strategy
14.2.3. Novartis AG
14.2.3.1. Overview
14.2.3.2. Product and End User Portfolio
14.2.3.3. Production Footprint
14.2.3.4. Sales Footprint
14.2.3.5. Channel Footprint
14.2.3.6. Strategy
14.2.3.6.1. Marketing Strategy
14.2.3.6.2. Product Strategy
14.2.3.6.3. Channel Strategy
14.2.4. Pfizer, Inc.
14.2.4.1. Overview
14.2.4.2. Product and End User Portfolio
14.2.4.3. Production Footprint
14.2.4.4. Sales Footprint
14.2.4.5. Channel Footprint
14.2.4.6. Strategy
14.2.4.6.1. Marketing Strategy
14.2.4.6.2. Product Strategy
14.2.4.6.3. Channel Strategy
14.2.5. Moberg Pharma AB
14.2.5.1. Overview
14.2.5.2. Product and End User Portfolio
14.2.5.3. Production Footprint
14.2.5.4. Sales Footprint
14.2.5.5. Channel Footprint
14.2.5.6. Strategy
14.2.5.6.1. Marketing Strategy
14.2.5.6.2. Product Strategy
14.2.5.6.3. Channel Strategy
14.2.6. Johnson & Johnson Services, Inc.
14.2.6. Overview
14.2.6.2. Product and End User Portfolio
14.2.6.3. Production Footprint
14.2.6.4. Sales Footprint
14.2.6.5. Channel Footprint
14.2.6.6. Strategy
14.2.6.6.1. Marketing Strategy
14.2.6.6.2. Product Strategy
14.2.6.6.3. Channel Strategy
14.2.7. Bayer AG
14.2.7.1. Overview
14.2.7.2. Product and End User Portfolio
14.2.7.3. Production Footprint
14.2.7.4. Sales Footprint
14.2.7.5. Channel Footprint
14.2.7.6. Strategy
14.2.7.6.1. Marketing Strategy
14.2.7.6.2. Product Strategy
14.2.7.6.3. Channel Strategy
14.2.8. Dr. Reddy’s Laboratories Ltd.
14.2.8.1. Overview
14.2.8.2. Product and End User Portfolio
14.2.8.3. Production Footprint
14.2.8.4. Sales Footprint
14.2.8.5. Channel Footprint
14.2.8.6.1. Strategy
14.2.8.6.1. Marketing Strategy
14.2.8.6.2. Product Strategy
14.2.8.6.3. Channel Strategy
14.2.9. Cipla Ltd.
14.2.9.1. Overview
14.2.9.2. Product and End User Portfolio
14.2.9.3. Production Footprint
14.2.9.4. Sales Footprint
14.2.9.5. Channel Footprint
14.2.9.5.1. Strategy Marketing Strategy
14.2.9.5.2. Product Strategy
14.2.9.5.3. Channel Strategy
14.2.10. Medimetriks Pharmaceuticals, Inc.
14.2.10.1. Overview
14.2.10.2. Product and End User Portfolio
14.2.10.3. Production Footprint
14.2.10.4. Sales Footprint
14.2.10.5. Channel Footprint
14.2.10.5.1. Strategy Marketing Strategy
14.2.10.5.2. Product Strategy
14.2.10.5.3. Channel Strategy

15. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2016-2020 and Forecast 2021–2031, By Region
15.1.Introduction/Key Findings
15.2.Historical Market Size (US$ Mn) Trend Analysis By Region, 2021-2031
15.3.Market Size (US$ Mn) Forecast By Region, 2021-2031
15.3.1. North America
15.3.2. Latin America
15.3.3. Europe
15.3.4. Asia Pacific
15.3.5. Middle East & Africa
15.4.Market Attractiveness Analysis By Region

16. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2016-2020 and Forecast 2021–2031, By Product Type
16.1.Introduction/Key Findings
16.2.Historical Market Size (US$ Mn) and Trend Analysis By Product Type, 2021-2031
16.2.1. Tablets
16.2.1.1. Rx
16.2.1.2. OTC
16.2.2. Nail Paints
16.2.2.1. Rx
16.2.2.2. OTC
16.3.Market Size (US$ Mn) and Forecast By Product Type, 2021-2031
16.4.Market Attractiveness Analysis By Product Type

17. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2016-2020 and Forecast 2021–2031, By Treatment Type
17.1.Introduction/Key Findings
17.2.Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2021-2031
17.2.1. Oral
17.2.2. Topical
17.3.Market Size (US$ Mn) Forecast By Treatment Type, 2021-2031
17.4.Market Attractiveness Analysis By Treatment Type

18. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2016-2020 and Forecast 2021–2031, By End User
18.1.Introduction/Key Findings
18.2.Historical Market Size (US$ Mn) Trend Analysis By End User, 2021-2031
18.2.1. Hospitals
18.2.2. Clinics
18.2.3. Independent Pharmacies
18.2.4. Mail Order Pharmacies
18.2.5. Drug Stores
18.3.Market Size (US$ Mn) Forecast By End User, 2021-2031
18.4.Market Attractiveness Analysis By End User

19. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2016-2020 and Forecast 2021–2031
19.1.Market Value Share Analysis By All Segment
19.2.Y-o-Y Growth Analysis By All Segment
19.3.Absolute $ Opportunity

20. Research Methodology

List of Table

Table 01: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 02: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 03: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Treatment Type
Table 04: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 05: North America Dermatophytic Onychomycosis Therapeutics Market Participants Presence (Intensity Mapping)
Table 06: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 07: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 08: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Treatment Type
Table 09: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 10: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 11: Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Participants Presence (Intensity Mapping)
Table 12: Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 13: Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 14: Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Treatment Type
Table 15: Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 16: Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Participants Presence (Intensity Mapping)
Table 17: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 18: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 19: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Treatment Type
Table 20: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 21: Latin America Dermatophytic Onychomycosis Therapeutics Market Participants Presence (Intensity Mapping)
Table 22: Middle-East & Africa Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 23: Middle-East & Africa Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 24: Middle-East & Africa Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Treatment Type
Table 25: Middle-East & Africa Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 26: Middle-East & Africa Dermatophytic Onychomycosis Therapeutics Market Participants Presence (Intensity Mapping)
Table 27: Global Dermatophytic Onychomycosis Therapeutic products Size (US$ Mn) 2016-2020 and Forecast 2021-2031 By Region,
Table 28: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 29: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Treatment Type
Table 30: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel


• 英文レポート名:Global Market Study on Dermatophytic Onychomycosis Therapeutics (DOT): Increasing Preference for Topical Treatment Complementing Market Growth
• 日本語訳:世界の皮膚糸状菌性爪真菌症治療薬(DOT)市場
• レポートコード:PMR21SE018お問い合わせ(見積依頼・ご注文・質問)